Pioneering Pharmaceuticals
Making pharmaceuticals more affordable, more available, and better than before
Innovative solutions along the entire pharmaceutical value chain
As part of the TIEFENBACHER GROUP, a 100% family-owned leading health care company, we provide solutions throughout the entire life cycle of a pharmaceutical product. We develop, manufacture, and register innovative as well as generic drugs for our B2B customers. The world´s most trusted brands count on our high excellence in creating best-in-class-dossiers and our ability to manage complex launches in over 80 countries worldwide. Our own laboratories and manufacturing sites empower us to build up efficient supply chains resulting in best value for money for our customers.
There is one purpose driving TIEFENBACHER´s over 600 employees day by day: improving the life of millions of patients worldwide by making pharmaceuticals more affordable, more available, and better than before.
Driving force for advanced medicines
The numbers speak for us
>500million
patients served every year
600+
employees worldwide
180+
dossiers developed/ under development
40+
projects in pipeline
>500million
patients served every year
~600
employees worldwide
100+
dossiers developed
40+
development projects running
>3billion
units inhouse production capacity per year
15.000+
marketing authorizations obtained
80+
different countries where products are being sold
150+
active customers on five continents
~3bn
units production capacity per year
15.000+
marketing authorizations obtained
80+
different countries where products are being sold
150+
active customers on five continents
AET: Specialized in the Development and Commercialization of pharmaceuticals
Our purpose - Care for patients´ health by offering:
We are TIEFENBACHER GROUP
News
TIEFENBACHER PHARMACEUTICALS announces global launch of Teriflunomide making multiple sclerosis therapy more affordable and better available worldwide
TIEFENBACHER PHARMACEUTICALS, part of TIEFENBACHER GROUP, has successfully developed a global dossier for a generic version of Teriflunomide 7 mg and 14 mg film-coated tablets. Teriflunomide is an…
AET Pharma US Inc. Announces Successful approval of generic Posaconazole by the Food and Drug Administration (FDA)
On 1st February 2021, AET Pharma US Inc, part of TIEFENBACHER GROUP, received FDA approval of the Abbreviated New Drug Application (ANDA) for Posaconazole 100 mg Delayed-Release Tablets. This is…
Global Presence – on five continents
Our path to profitable growth: Creating breakthrough pharmaceuticals
80+
countries
80+
countries
Contact – Partner with us
As the builders of the future, we´re working to improve patients´ lives. By thinking beyond healthcare.
ALFRED E. TIEFENBACHER (GmbH & Co. KG)
Van-der-Smissen-Strasse 1
22767 Hamburg
Germany
Phone: +49 40 – 44 18 09 – 0
Fax: +49 40 – 44 18 09 – 26
Mail: info@aet.eu